Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ferring Pharmaceuticals
Degarelix was not FDA regulated at the time of the trial. After completion of the trial degarelix has been approved by the FDA and is thus an FDA regulated intervention.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Signed informed consent before any trial related activity
Proven prostate cancer with a need for endocrine treatment
Testosterone level within the normal range for the age
You may not be if
Previous or current hormonal treatment of prostate cancer
Candidate for prostatectomy or radiotherapy
History of severe asthma, anaphylactic reactions or Quincke's Oedema
Hypersensitivity towards any component of FE200486
Cancer disease within the last ten years except for prostate cancer and some skin cancers
Presenting with significant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, haematological, dermatological or infectious disorder. In addition any other condition such as excessive alcohol or drug abuse that may interfere with trial participation or influence the conclusion of the trial as judged by the investigator
Mental incapacity or language barrier
Having received an investigational product within the last 12 weeks preceding the trial
Previous participation in this trial
Clareo Health | The Efficacy and Safety of FE 200486 in Treatment of Patients Suffering From Prostate Cancer
